

US012029779B2

(12) United States Patent

Groenning et al.

(10) Patent No.: US 12,029,779 B2

(45) **Date of Patent:** Jul. 9, 2024

(54) SEMAGLUTIDE IN MEDICAL THERAPY

(71) Applicant: Novo Nordisk A/S, Bagsvaerd (DK)

(72) Inventors: Marianne Oelholm Larsen Groenning, Hareskov (DK); Lars Endahl, Lyngby (DK); Charlotte Giwercman Carson, Copenhagen (DK); Anders Bjerring Strathe, Farum (DK); Maria Kabisch, Koebenhavn S (DK); Thomas Hansen, Broenshoej

(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 16/844,552

(22) Filed: Apr. 9, 2020

(65) **Prior Publication Data**

(DK)

US 2020/0237876 A1 Jul. 30, 2020

Related U.S. Application Data

(63) Continuation of application No PCT/EP2018/077654, filed on Oct. 10, 2018.

(30) Foreign Application Priority Data

Oct.	12, 2017	(EP)	•••••	17196254
------	----------	------	-------	----------

(51) Int. Cl.

A61K 38/26 (2006.01)

A61K 9/00 (2006.01)

A61P 3/04 (2006.01)

(58) Field of Classification Search

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

7,799,344 B2	9/2010	Oberg
8,114,833 B2	2/2012	Pedersen et al.
8,129,343 B2	3/2012	Lau et al.
8,536,122 B2	9/2013	Lau et al.
8,748,376 B2	6/2014	Ludvigsen et al.
8,846,618 B2	9/2014	Flink et al.
10,000,542 B2	6/2018	Kofoed et al.
2007/0203058 A1	8/2007	Lau et al.
2010/0047762 A1	2/2010	Button et al.
2010/0292133 A	11/2010	Spetzler et al.
2011/0301080 A1	12/2011	Bush et al.
2015/0232527 A1	8/2015	Gong et al.
2016/0108102 A	4/2016	Lau et al.
2019/0231876 A1	8/2019	Pedersen et al.

FOREIGN PATENT DOCUMENTS

CN	102229668 A 11/2011
CN	104519902 A 4/2015
RU	2409349 C2 1/2011
RU	2413530 C2 3/2011
WO	2005/027978 A2 3/2005
WO	2005049061 A2 6/2005
WO	2006/097537 A2 9/2006
WO	2010/092163 A2 8/2010
WO	2011080103 A1 7/2011
WO	2011138421 A1 11/2011
WO	WO 2011/138421 * 11/2011
WO	12016419 A1 2/2012
WO	2012080471 A1 6/2012
WO	2012088379 A2 6/2012
WO	2012107476 A1 8/2012
WO	12130136 A1 10/2012
WO	12136790 A1 10/2012
WO	2012177929 A2 12/2012
WO	2014005858 1/2014
WO	WO 2014/005858 * 1/2014
WO	2014177683 A1 11/2014
WO	WO 2014/177683 * 11/2014
WO	2017112824 6/2017
0	201.112021 0/201/

OTHER PUBLICATIONS

Ahmann et al., "Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3)," Diabetes Research and Clinical Practice, 2016, vol. 120, p. S51.

Anonymous: "NCT02453711 on Jul. 26, 2017: ClinicalTrials.gov Archive," Retrieved from Internet: URL:https://clincialtrials.gov/archive/NCT02453711/2017_07_26, retrieved on Jan. 26, 2018. Aroda et al., "Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine in Insulin-Naive Subjects with Type 2 Diabetes (SUSTAIN 4)," Diabetes Research and Clinical Practice, 2016, vol. 120, p. S51.

Blundell et al., "Effects of once-weekly Semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity," Diabetes Obes Metab, 2017, vol. 19, pp. 1242-1251.

Chow et al., "Efficacy and Safety of Once-Weekly Semaglutide Versus Sitagliptin as Add-On to Metformin and/or Thiazolidinediones in Subjects with T2D (Sustain 2)," Diabetes Research and Clinical Practice, 2016, vol. 120, p. S122.

Davies et al., "Dose-dependent glucose lowering and body weight reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes," Abstract 149, Diabetologia, 2016, vol. 59, Suppl. 1, p. S77.

Davies et al., "Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes," JAMA, 2017, vol. 218, No. 15, pp. 1460-1470.

(Continued)

Primary Examiner — Sergio Coffa

(74) Attorney, Agent, or Firm — Leon Y. Lum

(57) ABSTRACT

The present invention relates to semaglutide for use in weight management.

14 Claims, No Drawings